1. Signaling Pathways
  2. Apoptosis
  3. RIP kinase

RIP kinase

Receptor-interacting protein kinases; RIPK

Receptor-interacting protein (RIP) kinases are a group of threonine/serine protein kinases with a relatively conserved kinase domain but distinct non-kinase regions. There are seven members of the RIPK family, RIPK1-7, some of which have emerged as critical effectors of immunity to infection with a diverse array of bacterial, viral, and protozoal pathogens.

RIP kinases are cellular signaling molecules that are critical for homeostatic signaling in both communicable and non-communicable disease processes. RIPK1, RIPK2, RIPK3 and RIPK7 have emerged as key mediators of intracellular signal transduction including inflammation, autophagy and programmed cell death, and are thus essential for the early control of many diverse pathogenic organisms.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-157325
    RIPK2-IN-5
    Inhibitor 99.73%
    RIPK2-IN-5 (compound 14) is a high affinity and excellent selectivity RIPK2 inhibitor with an IC50 value of 5.1nM. RIPK2-IN-5 has cellular anti-inflammatory effect and can reduce the secretion of MDP-induced TNF-α with a dose-dependent manner. RIPK2-IN-5 shows moderate stability in human liver microsome. RIPK2-IN-5 can be used for the research of immune diseases.
    RIPK2-IN-5
  • HY-128348
    PK68
    Inhibitor 99.92%
    PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis.
    PK68
  • HY-19628
    OD36
    Inhibitor 99.33%
    OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with KDs of 37 nM.
    OD36
  • HY-155782
    Zharp2-1
    Inhibitor 99.10%
    Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis.
    Zharp2-1
  • HY-153598
    LD4172
    Degrader 98.32%
    LD4172 is a selective RIPK1 PROTAC degrader with a Ki of 4.8 nM. LD4172 induces RIPK1 protein degradation via ternary complex formation with RIPK1 and VHL E3 ligase, driving ubiquitination and proteasomal breakdown. LD4172 abrogates TNF-induced classical NF-κB signaling in TRAF2-deficient cells, impairing IκBα phosphorylation and degradation, and reducing IL-8 production. LD4172 induces apoptosis and immunogenic cell death in tumor cells, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy. LD4172 acts as a chemical probe for investigating RIPK1 scaffolding functions. LD4172 can be used for the research of melanoma, colon cancer.
    LD4172
  • HY-100131
    GSK481
    Inhibitor 98.04%
    GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC50 of 1.3 nM, which inhibits Ser166 phosphorylation in wild-type human RIP1 (IC50=2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC50 of 10 nM.
    GSK481
  • HY-111870
    PROTAC RIPK degrader-6
    Inhibitor 99.01%
    PROTAC RIPK degrader-6 (example 1) is a Cereblon-based PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder.
    PROTAC RIPK degrader-6
  • HY-B0339R
    Primidone (Standard)
    Inhibitor
    Primidone (Standard) is the analytical standard of Primidone. This product is intended for research and analytical applications. Primidone is the orally active inhibitor for TRPM3 (IC50 = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent.
    Primidone (Standard)
  • HY-18901
    RIPK1-IN-4
    Inhibitor 98.89%
    RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase.
    RIPK1-IN-4
  • HY-161060
    Zharp1-211
    Inhibitor 99.15%
    Zharp1-211 is a RIPK1 kinase inhibitor with an EC50 of 53 nM and a Kd of 8.7 nM. Zharp1-211 reduces IFN-γ-induced STAT1 activation. Zharp1-211 can be used in the research of graft-versus-host disease and colon cancer.
    Zharp1-211
  • HY-115630
    cRIPGBM chloride
    99.82%
    cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models.
    cRIPGBM chloride
  • HY-112038
    GSK2983559 free acid
    Inhibitor 99.49%
    GSK2983559 free acid (compound 3) is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 free acid can block many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.
    GSK2983559 free acid
  • HY-122665
    HTH-01-091
    Inhibitor 99.81%
    HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research.
    HTH-01-091
  • HY-161059
    ZB-R-55
    Inhibitor 99.39%
    ZB-R-55 is an orally active and selective dual-mode RIPK1 inhibitor with RIPK1 IC50 values of 5.7 nM. ZB-R-55 occupies both the allosteric and ATP binding sites of RIPK1. ZB-R-55 inhibits necroptosis in cancer cells. ZB-R-55 can be used for the research of systemic inflammatory response syndrome and sepsis.
    ZB-R-55
  • HY-152846
    Flizasertib
    Inhibitor 99.9%
    Flizasertib (GDC-8264) is an orally active, reversible and selective RIP1 inhibitor with Kiapp values of 0.00071 μM and 0.0013 μM for human and cynomolgus monkey RIP1 kinase, respectively. Flizasertib blocks RIP1 autophosphorylation but does not affect RIP1 protein stability. Flizasertib inhibits pro-inflammatory cytokines (CCL3, CCL4, and IL-1β) production. Flizasertib results in inhibition of colitis and ileitis. Flizasertib can be used in the research of cardiac surgery-associated acute kidney injury.
    Flizasertib
  • HY-157039
    RIPK1-IN-17
    Inhibitor
    RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor (Kd = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS).
    RIPK1-IN-17
  • HY-RS11992
    RIPK1 Human Pre-designed siRNA Set A
    Inhibitor

    RIPK1 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RIPK1 Human Pre-designed siRNA Set A
  • HY-14622B
    Necrostatin 2 (S enantiomer)
    Inhibitor 99.76%
    Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2 (HY-14622). Necrostatin 2 S enantiomer inhibits TNF-α-induced necroptosis in Jurkat T cells. Necrostatin 2 S enantiomer can be used for the research of ischemic brain injury (stroke).
    Necrostatin 2 (S enantiomer)
  • HY-149393
    RIPK3-IN-3
    Inhibitor
    RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC50=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion.
    RIPK3-IN-3
  • HY-148239
    TP-030-2
    Inhibitor 98.17%
    TP-030-2, a chemical probe, is a RIPK1 inhibitor (human Ki=0.43 nM; mouse IC50=100 nM).
    TP-030-2
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.